The Effect of Metformin on Serum Gonadotropin Levels in Postmenopausal Women with Diabetes and Prediabetes: A Pilot Study

Abstract

Background Metformin was found to decrease serum levels of prolactin and thyrotropin. The aim of this study was to investigate the effect of this drug on hypothalamic-pituitary-ovarian axis activity in postmenopausal women with recently diagnosed and untreated glucose metabolism abnormalities.

Methods The study included three matched groups of postmenopausal women: patients with type 2 diabetes (group A, n=16), women with prediabetes (group B, n=14), and individuals with normal glucose metabolism (group C, n=14). Women with diabetes were then treated with high-dose metformin (3 g daily), while women with prediabetes received moderate doses of this agent (1.7 g daily). Glucose homeostasis markers, as well as serum levels of FSH, LH, thyrotropin, prolactin, estradiol and creatinine were measured at baseline and after 16 weeks of metformin treatment.

Results In both groups of metformin-treated women, the drug improved glucose homeostasis. High-dose metformin treatment reduced circulating levels of FSH and tended to reduce serum levels of LH, and these effects correlated with an improvement in insulin sensitivity. No changes in gonadotropin levels were observed in prediabetic women receiving moderate doses of metformin. Serum levels of thyrotropin, prolactin and estradiol, as well as the estimated glomerular filtration rate remained at a similar level throughout the study.

Conclusions Our study shows that the effect of metformin on hypothalamic-pituitary-ovarian axis activity in postmenopausal women depends on its dose and the magnitude of insulin resistance.

Key words

FSH - LH - menopause - metformin

• References

• 1 American Diabetes Association . Standards of medical care in diabetes – 2017. Pharmacological approaches to glycemic treatment. Diabetes Care 2017; 40 (Suppl. 01) S64-S74
• 2 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
• 3 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167
• 4 Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91: 225-227
• 5 Cappelli C, Rotondi M, Pirola I. et al. TSH-lowering effect of metformin in type 2 diabetic patients: Differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32: 1589-1590
• 6 Isidro ML, Penín MA, Nemiña R. et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32: 79-82
• 7 Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 8: 47-48
• 8 Lupoli R, Di Minno A, Tortora A. et al. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J Clin Endocrinol Metab 2014; 99: E143-E148
• 9 Krysiak R, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55: 45-49
• 10 Krysiak R, Gilowska M, Szkróbka W. et al. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. Pharmacol Rep 2016; 68: 490-494
• 11 Krysiak R, Okopień B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol 2011; 75: 404-406
• 12 Krysiak R, Okrzesik J, Okopień B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2015; 49: 242-249
• 13 Krysiak R, Kowalcze K, Szkrobka W. et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med 2016; 30: 94-98
• 14 Krysiak R, Szkróbka W, Okopień B. A neutral effect of metformin treatment on macroprolactin content in women with macroprolactinemia. Exp Clin Endocrinol Diabetes 2017; 125: 223-228
• 15 Oride A, Kanasaki H, Purwana IN. et al. Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs. Pituitary 2010; 13: 236-241
• 16 Genazzani AD, Battaglia C, Malavasi B. et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119
• 17 Velija-Ašimi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn J Basic Med Sci 2013; 13: 180-185
• 18 Billa E, Kapolla N, Nicopoulou SC. et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol 2009; 25: 427-443
• 19 Oleandri SE, Maccario M, Rossetto R. et al. Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest 1999; 22: 134-140
• 20 Labbuzek K, Suchy D, Gabryel B. et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62: 956-965
• 21 Ueno M. Molecular anatomy of the brain endothelial barrier: An overview of the distributional features. Curr Med Chem 2007; 14: 1199-1206
• 22 Krysiak R, Szkróbka W, Okopień B. Sex-dependent effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with subclinical hypothyroidism. Pharmacol Rep 2016; 68: 1115-1119
• 23 National Collaborating Centre for Women's and Children's Health (UK) . Menopause: Full Guideline. London: National Institute for Health and Care Excellence (UK); 2015. Nov 12
• 24 Ross LA, Polotsky AJ. Metabolic correlates of menopause: An update. Curr Opin Obstet Gynecol 2012; 24: 402-407
• 25 Krysiak R, Okopień B, Gdula-Dymek A. et al. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006; 58: 614-625
• 26 Weigert J, Neumeier M, Wanninger J. et al. Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Cytokine 2009; 45: 86-91
• 27 Tosca L, Froment P, Rame C. et al. Metformin decreases GnRH- and activin-induced gonadotropin secretion in rat pituitary cells: Potential involvement of adenosine 5' monophosphate-activated protein kinase (PRKA). Biol Reprod 2011; 84: 351-362
• 28 Nascimento AD, Silva Lara LA, Japur de Sá Rosa-e-Silva AC. et al. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol 2013; 29: 246-249
• 29 Feyereisen E, Méndez Lozano DH, Taieb J. et al. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online 2006; 12: 695-703
• 30 Edman CD. The climacteric. Buchsbaum, ed. The menopause. New York: Springer-Verlag; 1983: 23-32
• 31 Patil M. Gonadotrophins: the future. J Hum Reprod Sci 2014; 7: 236-248
• 32 Simpson E, Rubin G, Clyne C. et al. Local estrogen biosynthesis in males and females. Endocr Relat Cancer 1999; 6: 131-137
• 33 Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol 2011; 75: 1-9
• 34 Chau-Van C, Gamba M, Salvi R. et al. Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007; 148: 507-511
• 35 López M, Nogueiras R, Tena-Sempere M. et al. Hypothalamic AMPK: A canonical regulator of whole-body energy balance. Nat Rev Endocrinol 2016; 12: 421-432
• 36 López M, Varela L, Vázquez MJ. et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16: 1001-1008
• 37 McFadden SA, Menchella JA, Chalmers JA. et al. Glucose responsiveness in a novel adult-derived GnRH cell line, mHypoA-GnRH/GFP: Involvement of AMP-activated protein kinase. Mol Cell Endocrinol 2013; 377: 65-74
• 38 Aroda VR, Knowler WC, Crandall JP. et al. Metformin for diabetes prevention: Insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 2017; 60: 1601-1611
• 39 Genuth S. The UKPDS and its global impact. Diabet Med 2008; 25 (Suppl. 02) 57-62